Epithelioid sarcoma and its outcome: a retrospective analysis from a tertiary care center in North India

AIM: Clinicopatholgical findings and outcomes in epithelioid sarcoma (ES) patients. MATERIALS & METHODS: ES patients registered in sarcoma clinic from 2015 to 2021. RESULTS: There were 20 patients with median age of 26 years. Majority had distal ES (70%) and advanced disease (85%). In patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashyap, Divya, Rastogi, Sameer, Garg, Vikas, Shrivastava, Shakti, Barwad, Adarsh, Shamim, Shamim A, Hemrom, Angel, Dhamija, Ekta, Bhoriwal, Sandeep, Garg, Rakesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912277/
https://www.ncbi.nlm.nih.gov/pubmed/36788984
http://dx.doi.org/10.2144/fsoa-2021-0138
Descripción
Sumario:AIM: Clinicopatholgical findings and outcomes in epithelioid sarcoma (ES) patients. MATERIALS & METHODS: ES patients registered in sarcoma clinic from 2015 to 2021. RESULTS: There were 20 patients with median age of 26 years. Majority had distal ES (70%) and advanced disease (85%). In patients with advanced disease lymph nodes were involved in 65%, lungs in 58% and others in 35%. Among 14 patients who underwent biopsy outside our institute, nine (64.2 %) had been initially misdiagnosed. Response rates to doxorubicin (n = 12), pazopanib (n = 6), gemcitabine/docetaxel (n = 5), tazemetostat (n = 3) and immunotherapy (n = 2) used in various lines were 16, 16, 20, 33 and 0%, respectively. CONCLUSION: Our patients had an advanced-stage and distal ES, with a modest response to chemotherapy.

Ejemplares similares